NCT03893630View on ClinicalTrials.gov

Role of ASpirin in Placental and Maternal Endothelial Cell Regulation IN Pre-eclampsia

PHASE2CompletedINTERVENTIONAL
Enrollment

208

Participants

Timeline

Start Date

April 25, 2019

Primary Completion Date

July 26, 2022

Study Completion Date

September 28, 2022

Conditions
Pre-Eclampsia
Interventions
DRUG

Acetylsalicylic Acid 81 mg

Patients will receive 81mg acetylsalicylic acid daily, initiated between 11 and 16 weeks of gestation and continued until 36 weeks of gestation.

DRUG

Acetylsalicylic Acid 162 mg

Patients will receive 162mg acetylsalicylic acid daily, initiated between 11 and 16 weeks of gestation and continued until 36 weeks of gestation.

OTHER

Control

Standard of Care

Trial Locations (1)

40536

University of Kentucky, Lexington

All Listed Sponsors
lead

John O'Brien, MD

OTHER

NCT03893630 - Role of ASpirin in Placental and Maternal Endothelial Cell Regulation IN Pre-eclampsia | Biotech Hunter | Biotech Hunter